Axitinib in advanced renal-cell carcinoma
Mené sur 288 patients atteints d'un carcinome rénal métastatique à cellules claires, cet essai international de phase III compare l'efficacité, du point de vue de la survie sans progression, et la toxicité de l'axitinib et du sorafenib
Despite poor tolerability and marginal efficacy, interferon alfa was standard therapy for advanced clear-cell renal-cell carcinoma until around 5 years ago. Since then, management of advanced disease has changed dramatically and several drugs targeting VEGF receptors have been approved. For example, a trial in 750 treatment-naive patients showed a 6 month improvement in median progression-free survival for sunitinib compared with interferon alfa. The COMPARZ trial, comparing sunitinib with pazop ...
The Lancet Oncology , commentaire, 2012